Daniel L. Alkon

NeuroscienceMedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Advanced Alzheimer’s Disease Patients Show Safe, Significant, and Persistent Benefit in 6-Month Bryostatin Trial”.

Advanced Alzheimer’s Disease Patients Show Safe, Significant, and Persistent Benefit in 6-Month Bryostatin Trial

Journal of Alzheimer s Disease(2023)10.3233/jad-230868

N/A

0.416DataRank · unranked

15 citations

Miao‐Kun Sun, Alan J. Tuchman, Richard E. Thompson, Daniel L. Alkon

Bryostatin Placebo-Controlled Trials Indicate Cognitive Restoration Above Baseline for Advanced Alzheimer’s Disease in the Absence of Memantine1

Journal of Alzheimer s Disease(2022)10.3233/jad-215545

N/A

0DataRank · unranked

24 citations

Alan J. Tuchman, Daniel L. Alkon, Richard E. Thompson

Alzheimer’s therapeutic development: shifting neurodegeneration to neuroregeneration

Trends in Pharmacological Sciences(2024)10.1016/j.tips.2024.01.012

N/A

0DataRank · unranked

8 citations

Daniel L. Alkon, Miao‐Kun Sun